Y Intercept Hong Kong Ltd Invests $1.45 Million in REGENXBIO Inc. $RGNX

Y Intercept Hong Kong Ltd purchased a new position in shares of REGENXBIO Inc. (NASDAQ:RGNX) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 176,999 shares of the biotechnology company’s stock, valued at approximately $1,453,000. Y Intercept Hong Kong Ltd owned about 0.35% of REGENXBIO as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also modified their holdings of RGNX. Brooklyn Investment Group lifted its position in shares of REGENXBIO by 163.7% during the first quarter. Brooklyn Investment Group now owns 5,583 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 3,466 shares during the last quarter. Entropy Technologies LP acquired a new stake in REGENXBIO during the first quarter worth about $107,000. Wealth Enhancement Advisory Services LLC acquired a new stake in REGENXBIO during the first quarter worth about $123,000. Caliber Wealth Management LLC KS acquired a new stake in REGENXBIO during the first quarter worth about $126,000. Finally, Pallas Capital Advisors LLC raised its stake in REGENXBIO by 67.1% during the second quarter. Pallas Capital Advisors LLC now owns 17,407 shares of the biotechnology company’s stock worth $143,000 after acquiring an additional 6,992 shares during the period. Institutional investors own 88.08% of the company’s stock.

REGENXBIO Trading Down 0.4%

Shares of NASDAQ:RGNX opened at $12.77 on Monday. The firm’s 50 day moving average is $10.52 and its two-hundred day moving average is $9.35. REGENXBIO Inc. has a 52 week low of $5.03 and a 52 week high of $13.93. The firm has a market capitalization of $645.06 million, a P/E ratio of -3.71 and a beta of 1.17.

REGENXBIO (NASDAQ:RGNX) last announced its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($1.38) EPS for the quarter, missing the consensus estimate of ($1.13) by ($0.25). REGENXBIO had a negative net margin of 112.70% and a negative return on equity of 66.95%. The firm had revenue of $21.36 million during the quarter, compared to analyst estimates of $40.87 million. Analysts predict that REGENXBIO Inc. will post -4.84 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on RGNX. Weiss Ratings reiterated a “sell (d-)” rating on shares of REGENXBIO in a research note on Wednesday, October 8th. Chardan Capital reiterated a “buy” rating and set a $52.00 price objective on shares of REGENXBIO in a research note on Monday, September 8th. Barclays dropped their price objective on shares of REGENXBIO from $50.00 to $37.00 and set an “overweight” rating on the stock in a research note on Friday, August 8th. Royal Bank Of Canada dropped their price objective on shares of REGENXBIO from $21.00 to $17.00 and set an “outperform” rating on the stock in a research note on Friday, August 8th. Finally, HC Wainwright reiterated a “buy” rating and set a $34.00 price objective on shares of REGENXBIO in a research note on Tuesday, October 7th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $28.38.

Insider Activity

In other news, CEO Curran Simpson sold 20,811 shares of the stock in a transaction that occurred on Thursday, October 9th. The shares were sold at an average price of $12.62, for a total value of $262,634.82. Following the completion of the transaction, the chief executive officer directly owned 216,162 shares in the company, valued at $2,727,964.44. This trade represents a 8.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have sold 36,169 shares of company stock valued at $416,598 in the last ninety days. Company insiders own 12.79% of the company’s stock.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.